Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of AZD1722 (tenapanor) in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
2013-005345-36Phase 2Completed
- Sponsor
- Ardelyx
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis comparing Tenapanor (AZD1722) with Placebo (2 arms). Primary endpoint: Change in urine albumin-to-creatinine ratio from baseline to Week 12. Started May 2014; status: completed.
02
Drugs
tenapanor
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2013-005345-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005345-36.